Patient-specific tumor-associated antigens presented on MHC molecules of semi-allogeneic fibroblasts

Patient-specific tumor-associated antigens presented on MHC molecules of semi-allogeneic fibroblasts refers to a specialized therapeutic complex used in personalized cancer vaccines. This approach involves engineering fibroblasts to express a patient's unique profile of tumor-associated antigens (TAAs), which are then processed and displayed on the cell surface via Major Histocompatibility Complex (MHC) molecules (Fakhrai et al., 2004, Journal of Immunotherapy). The use of semi-allogeneic fibroblasts—cells that share some but not all HLA alleles with the patient—is designed to provide a dual-action immune stimulus. The shared HLA alleles allow the fibroblasts to directly present the TAAs to the patient's T-cells, while the mismatched alleles trigger a potent allogeneic response that acts as a natural adjuvant (Hodge et al., 1995, Cancer Research). This combined effect is intended to overcome tumor-induced immune suppression and prime the immune system to recognize and attack cancer cells expressing those specific antigens throughout the body. Clinical applications of this technology, such as the Morpheus-1 vaccine, have been investigated for various solid tumors, including glioblastoma and melanoma (ClinicalTrials.gov, NCT00003919). This platform represents a bridge between autologous and allogeneic cell therapies, leveraging the benefits of both to enhance anti-tumor immunity.

Other names

Semi-allogeneic fibroblast vaccinePersonalized fibroblast-based tumor antigen presentationMHC-presented tumor-associated antigens (semi-allogeneic)Morpheus-1 vaccine complex

Induction of a systemic, patient-specific T-cell mediated immune response against tumor-associated antigens via MHC-restricted presentation and allogeneic adjuvant effect.